

Active substances set

Search phrase: nivolumab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant stomach cancer

Nivolumab

Nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) \geq 5.

 **FULL REIMBURSEMENT**
 **ESMO**

Colon and rectum cancer

Nivolumab

Nivolumab in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) after prior fluoropyrimidine-based combination chemotherapy.

 **NO REIMBURSEMENT**
 **ESMO**

Tracheal, bronchus, and lung cancer

Nivolumab

Nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation. Nivolumab as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults.

Nivolumab in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression $\geq 1\%$.

 **REIMBURSEMENT
WITH RESTRICTIONS**

 **ESMO**

Kidney cancer

Nivolumab

Nivolumab as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults.

Nivolumab in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma.

Nivolumab in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.

 **REIMBURSEMENT
WITH RESTRICTIONS**

 **ESMO**

Malignant bladder cancer

Nivolumab

Urothelial carcinoma Nivolumab in combination with cisplatin and gemcitabine is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. Nivolumab as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. Adjuvant treatment of urothelial carcinoma Nivolumab as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression $\geq 1\%$, who are at high risk of recurrence after undergoing radical resection of MIUC.

 **REIMBURSEMENT
WITH RESTRICTIONS**

 **ESMO**

Hodgkin's disease

Nivolumab

Nivolumab as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.



**FULL
REIMBURSEMENT**



ESMO